ATH 2.86% 3.4¢ alterity therapeutics limited

Biogen Paper

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

    James Ferrero, et al.
    Abstract

    Introduction
    Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD).
    Methods

    This randomized, double-blind, placebo-controlled single ascending-dose study investigated the safety, tolerability, and pharmacokinetics (PK) of aducanumab in patients with mild-to-moderate AD. Eligible patients were sequentially randomized 6:2 to aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg) or placebo.
    Results

    The primary outcome was safety and tolerability. Doses ≤30 mg/kg were generally well tolerated with no severe or serious adverse events (SAEs). All three patients who received 60-mg/kg aducanumab developed SAEs of symptomatic amyloid-related imaging abnormalities, which completely resolved by weeks 8–15. Aducanumab Cmax, AUC0–last, and AUCinf increased in a dose-proportional manner.
    Discussion

    In this single-dose study, aducanumab demonstrated an acceptable safety and tolerability profile and linear PK at doses ≤30 mg/kg (clinicaltrials.gov NCT01397539).

    "Although there was an increase in plasma levels of Ab40 and Ab42 at 60 mg/kg, aducanumab did not appear
    to significantly affect plasma levels of Ab40 or Ab42 at the lower doses (0.3 mg/kg to 30 mg/kg). The largely unaffected soluble Ab levels are consistent with the very low affinity of aducanumab for soluble monomeric Ab. At 60 mg/kg, both Ab40 and Ab42 also demonstrated higher baseline/pre-dose values and higher patient variability than the lower dose cohort patients, thus complicating the interpretation. No dose-dependent response was observed for change in mean ADAS-Cog 13 scores after single-dose administration of aducanumab."

 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
3.4¢
Change
-0.001(2.86%)
Mkt cap ! $70.85M
Open High Low Value Volume
3.5¢ 3.6¢ 3.4¢ $501.6K 14.46M

Buyers (Bids)

No. Vol. Price($)
2 328946 3.4¢
 

Sellers (Offers)

Price($) Vol. No.
3.6¢ 472653 3
View Market Depth
Last trade - 16.10pm 03/03/2021 (20 minute delay) ?
(live)
Last
3.4¢
  Change
-0.001 ( 5.56 %)
Open High Low Volume
3.5¢ 3.6¢ 3.3¢ 3473672
Last updated 15.56pm 03/03/2021 (live) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.